|
|
 |
|
Total Number of Holdings (excluding cash): 50
| Merck & Co., Inc. |
MRK |
58933Y105 |
Pharmaceuticals |
11,672 |
$1,525,763.84 |
7.87% |
| Pfizer Inc. |
PFE |
717081103 |
Pharmaceuticals |
55,877 |
$1,411,453.02 |
7.28% |
| AbbVie Inc. |
ABBV |
00287Y109 |
Pharmaceuticals |
8,430 |
$1,410,254.70 |
7.27% |
| Johnson & Johnson |
JNJ |
478160104 |
Pharmaceuticals |
9,196 |
$1,350,156.72 |
6.96% |
| Bristol-Myers Squibb Company |
BMY |
110122108 |
Pharmaceuticals |
29,243 |
$1,307,162.10 |
6.74% |
| Amgen Inc. |
AMGN |
031162100 |
Pharmaceuticals |
2,710 |
$730,019.80 |
3.77% |
| Eli Lilly and Company |
LLY |
532457108 |
Pharmaceuticals |
985 |
$713,996.95 |
3.68% |
| United Therapeutics Corporation |
UTHR |
91307C102 |
Pharmaceuticals |
2,980 |
$703,131.00 |
3.63% |
| Vertex Pharmaceuticals Incorporated |
VRTX |
92532F100 |
Pharmaceuticals |
1,764 |
$701,542.80 |
3.62% |
| Biogen Inc. |
BIIB |
09062X103 |
Biotechnology |
3,420 |
$692,413.20 |
3.57% |
| Cardinal Health, Inc. |
CAH |
14149Y108 |
Pharmaceuticals |
6,627 |
$687,948.87 |
3.55% |
| Viatris Inc. |
VTRS |
92556V106 |
Pharmaceuticals |
59,988 |
$688,062.36 |
3.55% |
| Regeneron Pharmaceuticals, Inc. |
REGN |
75886F107 |
Biotechnology |
768 |
$684,042.24 |
3.53% |
| Gilead Sciences, Inc. |
GILD |
375558103 |
Pharmaceuticals |
10,292 |
$671,758.84 |
3.46% |
| Jazz Pharmaceuticals Plc |
JAZZ |
G50871105 |
Pharmaceuticals |
5,476 |
$588,286.68 |
3.03% |
| Zoetis Inc. |
ZTS |
98978V103 |
Pharmaceuticals |
3,741 |
$573,719.76 |
2.96% |
| Organon & Co. |
OGN |
68622V106 |
Pharmaceuticals |
29,373 |
$541,050.66 |
2.79% |
| Charles River Laboratories International, Inc. |
CRL |
159864107 |
Biotechnology |
1,741 |
$396,617.21 |
2.05% |
| Perrigo Company Plc |
PRGO |
G97822103 |
Pharmaceuticals |
9,502 |
$297,127.54 |
1.53% |
| Medpace Holdings, Inc. |
MEDP |
58506Q109 |
Biotechnology |
746 |
$290,768.42 |
1.50% |
| Halozyme Therapeutics, Inc. |
HALO |
40637H109 |
Biotechnology |
6,419 |
$246,874.74 |
1.27% |
| Alkermes Plc |
ALKS |
G01767105 |
Pharmaceuticals |
7,756 |
$189,556.64 |
0.98% |
| Exelixis, Inc. |
EXEL |
30161Q104 |
Biotechnology |
8,089 |
$190,334.17 |
0.98% |
| Incyte Corporation |
INCY |
45337C102 |
Biotechnology |
3,570 |
$182,712.60 |
0.94% |
| Neurocrine Biosciences, Inc. |
NBIX |
64125C109 |
Biotechnology |
1,288 |
$177,434.88 |
0.92% |
| Prestige Consumer Healthcare Inc. |
PBH |
74112D101 |
Pharmaceuticals |
2,341 |
$164,197.74 |
0.85% |
| Elanco Animal Health Incorporated |
ELAN |
28414H103 |
Pharmaceuticals |
10,317 |
$134,533.68 |
0.69% |
| Illumina, Inc. |
ILMN |
452327109 |
Biotechnology |
992 |
$120,081.60 |
0.62% |
| Exact Sciences Corporation |
EXAS |
30063P105 |
Biotechnology |
1,801 |
$105,880.79 |
0.55% |
| Intra-Cellular Therapies, Inc. |
ITCI |
46116X101 |
Biotechnology |
1,491 |
$107,545.83 |
0.55% |
| Sarepta Therapeutics, Inc. |
SRPT |
803607100 |
Biotechnology |
810 |
$103,185.90 |
0.53% |
| Blueprint Medicines Corporation |
BPMC |
09627Y109 |
Pharmaceuticals |
1,108 |
$100,528.84 |
0.52% |
| Krystal Biotech, Inc. |
KRYS |
501147102 |
Biotechnology |
650 |
$101,192.00 |
0.52% |
| BioMarin Pharmaceutical Inc. |
BMRN |
09061G101 |
Pharmaceuticals |
1,201 |
$98,686.17 |
0.51% |
| Roivant Sciences Ltd. |
ROIV |
G76279101 |
Biotechnology |
9,059 |
$98,561.92 |
0.51% |
| Arcellx, Inc. |
ACLX |
03940C100 |
Biotechnology |
1,885 |
$96,851.30 |
0.50% |
| Merus NV |
MRUS |
N5749R100 |
Biotechnology |
2,138 |
$96,060.34 |
0.50% |
| Ionis Pharmaceuticals, Inc. |
IONS |
462222100 |
Pharmaceuticals |
2,292 |
$95,897.28 |
0.49% |
| Viking Therapeutics, Inc. |
VKTX |
92686J106 |
Biotechnology |
1,345 |
$92,616.70 |
0.48% |
| MoonLake Immunotherapeutics (Class A) |
MLTX |
61559X104 |
Biotechnology |
2,148 |
$90,753.00 |
0.47% |
| Rhythm Pharmaceuticals, Inc. |
RYTM |
76243J105 |
Biotechnology |
2,387 |
$91,064.05 |
0.47% |
| IDEAYA Biosciences, Inc. |
IDYA |
45166A102 |
Biotechnology |
2,319 |
$89,559.78 |
0.46% |
| Ultragenyx Pharmaceutical Inc. |
RARE |
90400D108 |
Biotechnology |
2,004 |
$87,875.40 |
0.45% |
| TG Therapeutics, Inc. |
TGTX |
88322Q108 |
Biotechnology |
6,018 |
$83,710.38 |
0.43% |
| Kymera Therapeutics, Inc. |
KYMR |
501575104 |
Biotechnology |
2,427 |
$80,940.45 |
0.42% |
| Nuvalent, Inc. (Class A) |
NUVL |
670703107 |
Biotechnology |
1,232 |
$81,398.24 |
0.42% |
| ACADIA Pharmaceuticals Inc. |
ACAD |
004225108 |
Biotechnology |
4,459 |
$72,726.29 |
0.38% |
| Arvinas, Inc. |
ARVN |
04335A105 |
Biotechnology |
2,254 |
$71,226.40 |
0.37% |
| CRISPR Therapeutics AG |
CRSP |
H17182108 |
Biotechnology |
1,231 |
$66,141.63 |
0.34% |
| Beam Therapeutics Inc. |
BEAM |
07373V105 |
Biotechnology |
2,624 |
$56,678.40 |
0.29% |
| US Dollar |
$USD |
|
Other |
48,751 |
$48,750.99 |
0.25% |
Holdings are subject to change.
The holdings information set forth above for the date indicated reflects creation and redemption transactions from the prior business day and may differ from the holdings information currently available from the Fund's custodian and accounting agent. With respect to the market value of the Fund's holdings set forth above, the pricing sources are generally third party vendors. The Fund ultimately relies on pricing information provided by the Fund's accounting agent.
|
|
The information presented is not intended to constitute an investment recommendation for, or advice to, any specific person. By providing this information, First Trust is not undertaking to give advice in any fiduciary capacity within the meaning of ERISA, the Internal Revenue Code or any other regulatory framework. Financial professionals are responsible for evaluating investment risks independently and for exercising independent judgment in determining whether investments are appropriate for their clients.
|